GLP-1 Receptor Agonists and Cancer: Separating Signal from Noise
The GLP-1 and cancer debate is increasingly being discussed not only as a safety question, but also as a prevention and pharmacovigilance question. Recent academic studies are examining whether glucagon-like peptide-1 receptor agonists are associated with cancer risk among adults...
